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Abstract
Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for patients with hematologic malignancies. Its
therapeutic effect is largely dependent on recognition of minor histocompatibility antigens (MiHA) by donor-derived CD8+ T
cells. Therefore, monitoring of multiple MiHA-specific CD8+ T cell responses may prove to be valuable for evaluating the
efficacy of allogeneic SCT. In this study, we investigated the use of the combinatorial encoding MHC multimer technique to
simultaneously detect MiHA-specific CD8+ T cells in peripheral blood of SCT recipients. Feasibility of this approach was
demonstrated by applying dual-color encoding MHC multimers for a set of 10 known MiHA. Interestingly, single staining
using a fluorochrome- and Qdot-based five-color combination showed comparable results to dual-color staining for most
MiHA-specific CD8+ T cell responses. In addition, we determined the potential value of combinatorial encoding MHC
multimers in MiHA identification. Therefore, a set of 75 candidate MiHA peptides was predicted from polymorphic genes
with a hematopoietic expression profile and further selected for high and intermediate binding affinity for HLA-A2.
Screening of a large cohort of SCT recipients resulted in the detection of dual-color encoded CD8+ T cells following MHC
multimer-based T cell enrichment and short ex vivo expansion. Interestingly, candidate MiHA-specific CD8+ T cell responses
for LAG3 and TLR10 derived polymorphic peptides could be confirmed by genotyping of the respective SNPs. These
findings demonstrate the potency of the combinatorial MHC multimer approach in the monitoring of CD8+ T cell responses
to known and potential MiHA in limited amounts of peripheral blood from allogeneic SCT recipients.
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Introduction
In HLA-identical allogeneic stem cell transplantation (SCT),
alloreactive CD8+ T cells specific for minor histocompatibility
antigens (MiHA) play a pivotal role in graft rejection, graft-versus-
host disease (GVHD) and the curative graft-versus-tumor (GVT)
response. Several MiHA have been molecularly defined with the
potential to induce a GVT response without inducing GVHD,
such as HA-1 [1–4], LRH-1 [5] and ACC-1 [6]. Although MiHA
can be regarded as the most dominant antigens in GVT immunity,
the CD8+ T cell response rate towards these antigens has not been
followed extensively in transplanted patients. Furthermore, most
analysis focused on the detection of CD8+ T cell responses to
single MiHA epitopes using conventional techniques such as
single-tetramer staining or the ELISPOT assay.
Fluorescent labeled peptide-major histocompatibility antigen
(MHC) complexes, known as MHC multimers, are excellent
reagents to monitor MiHA-specific T cell responses after SCT
and donor lymphocyte infusion (DLI) in peripheral blood of
transplanted patients. Especially, the recently developed combina-
torial encoding technique using dual-color encoded MHC multi-
mers is a very attractive approach to accurately detect multiple
MiHA-specific T cells in one sample [7]. The principle of this
method relies on the flow cytometric detection of a single T cell
population that is stained with different fluorochrome-labeledMHC
multimers. This dual-color encoded MHC multimer approach has
the ability to detect up to 15 different T cell populations when using
6 different fluorochromes [7]. Therefore, a key advantage
compared to single-tetramer staining is that the amount of patient
peripheral blood cells needed is equal to just one labeling, making
the technique very suitable when dealing with limited amounts of
patient material. The combinatorial encoding approach can
accommodate a wide range of different peptide-MHC multimers
for several HLA molecules, which can be readily produced through
UV-mediated ligand exchange [8,9]. The versatility of these two
methods makes the combinatorial encoding MHC multimer
technique an excellent monitoring tool for detecting MiHA-specific
CD8+ T cell responses against a panel of known MiHA.
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Furthermore, another potential application of the combinatorial
encoding MHC multimer approach could be its use to identify
new MiHA. Recently, the value of the method for antigen
discovery has been demonstrated for the identification of
melanoma-associated T cell epitopes [7]. Here, we explored the
use of the combinatorial MHC multimer technique for the
detection of CD8+ T cell responses in transplanted patients against
candidate MiHA defined through a reverse immunology ap-
proach. Interestingly, we detected peptide-specific dual-tetramer
positive CD8+ T cells against 8 out of 75 HLA-A2 binding
peptides that were predicted in silico from polymorphic hemato-
poietic-specific genes.
Collectively, our results illustrate that the combinatorial MHC
multimer method is a suitable technique to analyze patients after
SCT and DLI for the concurrent occurrence of MiHA-specific
CD8+ T cells targeting known MiHA or candidate MiHA
identified by reverse immunology approaches.
Results
Immunomonitoring of MiHA-specific CD8+ T cell
responses using combinatorial MHC multimer staining
The success rate of immunological responses in patients post-
SCT and DLI can be assessed by measuring the MiHA-specific T
cells present in the blood of the patient [1,2,5]. Since patient
material is often in short supply, we developed a technique that
can screen for multiple MiHA-specific T cells in a limited amount
of patient follow-up material. This technique makes use of dual-
color-encoded MHC multimers to detect multiple antigen-specific
T cells in one sample [7,10]. In order to set up such a MiHA-
multimer kit, we have chosen a set of 10 MiHA, each being
encoded by two different fluorochromes coupled to an MHC
multimer containing an individual peptide (Table 1).
To determine whether the developed MiHA-multimer kit is
suitable for the detection of multiple MiHA-specific T cells in
blood samples of transplanted patients, we selected a cohort of
patients transplanted with partially T-cell depleted stem cell grafts
from HLA- identical sibling donors. These patients also received
pre-emptive DLI if they did not develop significant GVHD after
SCT. These patients and their respective donor were typed for
MiHA mismatches using fluorescence-based competitive allele
specific PCR (Table 2). The selected SCT recipients were
mismatched for one or two MiHA with their HLA-identical
donor and no tetramer+ T cells were observed in pre-SCT
recipient PBMC (Table 2). For the disparate MiHA a dual-color
tetramer analysis was performed using both APC and PE labeled
tetramers (Figure 1A). Since double positive events were scored,
the dual-color tetramer stainings result in accurate detection of low
frequency MiHA-specific CD8+ T cells [10], even at relatively late
time points post-SCT. Specific detection of these low frequency
MiHA-specific-CD8+ T cell populations was verified after in vitro
stimulation of peripheral blood mononuclear cells (PBMC)
samples with MiHA peptide-pulsed EBV-LCL (Figure 1A).
Knowing the MiHA-specific T cell status of the patient samples,
we tested a second cryopreserved PBMC sample again by the new
five-color combinatorial encoding MiHA-multimer kit (Figure 1B).
Results of a representative patient (i.e. UPN348) can be seen in
Figure 2A. For this patient’s cryopreserved PBMC sample at 31
weeks post-SCT, we observed 0.11% HY.B7-tetramer+ cells using
dual-color staining (Figure 1A), compared to 0.04% by the five-
color MiHA-multimer kit (Figure 1B and 2A). Specific detection of
CD8+tetramer+ T cells was verified after in vitro stimulation of
PBMC samples with HY-B7 peptide-pulsed EBV-LCL, showing
0.17% HY-B7-tetramer+ cells with the MHC-multimer kit
(Figure 2B) compared to 0.15% by dual-color staining
(Figure 1A). All different MiHA-specific CD8+ T cells found by
dual-color staining could also be found in the thawed PBMC
samples analyzed by the new five-color combinatorial encoded
MiHA-multimer assay, although the frequency of MiHA-specific
cells was somewhat lower (Table 2). These data demonstrate that
circulating MiHA-specific CD8+ T cells can be detected
concurrently using a combinatorial encoding MiHA-multimer
kit, making this a valuable tool for immunomonitoring of SCT
recipients using a limited amount of patient material.
Identification of novel candidate MiHA by reverse
immunology
Next, we studied the feasibility of the combinatorial encoding
MHC-multimers as an identification tool for the discovery of novel
MiHA. In order to predict HLA-A2-restricted candidate MiHA
within hematopoietically restricted gene products, we developed
and tested an adaptable computer algorithm. An arbitrary
minimum predicted halftime of dissociation (T(K)) of 30 seconds
was set for candidate HLA-A2 restricted MiHA, based on
corroboration with known HLA-A2 peptide and MiHA binding
affinities, which indicated that a peptide with moderate HLA-A2
binding affinity would exhibit a predicted T(K) of .30 seconds.
Subsequently, candidate MiHA were further selected, based upon
either observed allele frequencies in Caucasians or allele
frequencies reported by dbSNP/HapMap. Typically, only those
candidate MiHA that had a reported allele frequency for the
candidate MiHA-positive allele between 15% and 46% were
pursued as candidate MiHA, since MiHA with frequencies within
this range yield a theoretical clinical applicability of more than
20% in HLA-A2 matched unrelated recipient-donor pairs.
Peptides of the predicted candidate MiHA were synthesized and
HLA-A2 monomers were generated using the UV-mediated
ligand exchange method [9]. All monomers were tested for stable
binding of the predicted epitope using an ELISA-based HLA-
affinity assay [9], which revealed that 75 out of 107 predicted
potential MiHA bind HLA-A2 with high (OD$1.25) or
intermediate (OD 0.4–1.24) affinity (Figure 3). As a positive
control for successful peptide exchange, viral (EBV, CMV, FLU)
HLA-A2 specific peptides were used, as well as negative controls of
not applying UV light or not adding any peptide at all (data not
shown). Peptides with low affinity to HLA-A2 (OD#0.4) were
discarded from further experiments and only MHC-monomers
Table 1. MHC multimers and combinatorial encoding
scheme as assembled in MiHA-multimer kit.
MiHA HLA
Peptide
sequence Reference Fluorochrome code
SMCY A2 FIDSYICQV [29] PE APC
HY B7 SPSVDKARAEL [30] PE Qdot605
HA-1 A2 VLHDDLLEA [3] PE Qdot655
LRH-1 B7 TPNQRQNVC [5] PE Qdot705
ADIR A2 SVAPALALAFPA [31] APC Qdot605
ACC-1 A24 DYLQYVLQI [6] APC Qdot655
HA-8 A2 RTLDKVLEV [32] APC Qdot705
SP110 A3 SLPRGTSTPK [22] Qdot605 Qdot655
PANE-1 A3 RVWDLPGVLK [18] Qdot605 Qdot705
HA-2 A2 YIGEVLVSV [33,34] Qdot655 Qdot705
doi:10.1371/journal.pone.0021266.t001
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harboring peptides that bound with high or intermediate strength
were used for multimerization. This set of MHC multimers was
color coded, resulting in 5 pools of 15 different MHC multimers
and 1 pool of 4 different MHC multimers (Supplemental Table
S1). In addition to the predicted potential MiHA, pool A-D
contained control MHC multimers for the MiHA HA-1.A2, HA-
2.A2, HA-8.A2 and SMCY.A2.
Concurrent detection of multiple peptide-specific CD8+ T
cells after enrichment and expansion
To investigate whether peptide-specific CD8+ T cells could be
found for the predicted MiHA epitopes that had high or
intermediate affinity to HLA-A2, a cohort of 31 patients was
selected for screening of the follow-up material collected after DLI.
Approximately half of the patients selected, developed acute
GVHD after SCT and/or acute or chronic GVHD after DLI.
These observations show the presence of an allo-response that
might have been mediated by MiHA-specific T cells making these
patients attractive to look for candidate MiHA. To detect epitope-
specific-CD8+ T cells in the patient PBMC collected after DLI
(average 18 weeks post DLI) we first enriched the samples using
PE-labeled MHC multimers. Figure 4 shows an example of an
enriched culture containing low frequency CD8+ T cells specific
for the HLA-A2-restricted EBV (GLCTLVAML) and CMV
(NLVPMVATV) epitopes (respectively 0.03% and 0.38%) pre-
culture. MHC multimer-based enrichment and subsequent
expansion yielded a CD8+ T cell population consisting of 0.85%
EBV-TET+ and 11.5% CMV-TET+ cells after 16 days of
culturing. This shows the potential of this method to increase
low frequency T cells to sufficient cell numbers of multiple
specificities for further experiments.
To detect multiple MiHA peptide-specific CD8+ T cells against
our pre-selected panel of 75 candidate HLA-A2-restricted
peptides, we performed enrichments on 31 different patient
samples of which 17 resulted in sufficient cell numbers for analysis.
We detected peptide-specific CD8+ T cells in cultures of 5 different
patients (Table 3). Notably, we detected a CD8+ T cell response
against the known MiHA SMCY.A2. Additional patients were
transplanted with donor grafts mismatched for any of the control
HLA-A2 MiHA included in the analysis as was determined by
SNP genotyping. However, we did not observe specific T-cell
responses for these MiHA. Results of a representative patient
(UPN665) are shown in Figure 5A. PBMC from this patient
obtained at 14 weeks post DLI were enriched, expanded and
analyzed for all 6 combinatorial MHC-multimer encoding pools.
In pool A, two specific T cell populations were found. The
combination of multimers coupled to APC and Qdot705 showed a
positive response of 0.55% dual-color tetramer positive T cells,
recognizing the WT-1-derived epitope RMFPNAPYL. In addi-
tion, the combination of multimers coupled to Qdot605 and
Qdot655 showed a positive response of 0.07% dual-color tetramer
positive T cells, recognizing the BPI-derived epitope KLQ-
PYFQTL.
To verify whether the observed T cell responses correlate with
SNP mismatches at the DNA level, we performed allele specific
genotyping of donor and recipient for the SNPs corresponding to
the immunogenic epitopes found in the combinatorial MHC-
multimer staining. Although several mismatched SNPs between
donor and recipient were found, only 2 out of 8 epitopes found in
the screening corresponded with their respective SNP genotype
(underlined in Table 3). These two candidate MiHA (i.e. LAG3
derived LTLGVLSLL and CARD100 derived YLVPSDALL), as
well as epitopes to which a high response was observed (epitopes
derived from WT-1 and TLR10), were selected for further
experiments. However, dual-color tetramer stainings using PE-
and APC-conjugated tetramers could not confirm specific CD8+ T
cells for the found peptides in non-cultured PBMC. Although we
were not able to verify responses found in the analysis, the use of
combinatorial encoding MHC multimer panels proved useful for
high throughput concurrent detection of specific CD8+ T cells
against a large panel of candidate MiHA peptides.
Discussion
The monitoring of multiple MiHA-specific T cells in vivo can
give important additional information on the clinical response and
might lead to more insight into the therapeutic applicability of
specific MiHA. In this study, we report a novel approach for the
monitoring of MiHA-specific T cells in a limited number of PBMC
from patients after SCT and DLI, which we believe is of great
value for the immunomonitoring of SCT recipients. Cryopre-
served PBMC samples from patients who underwent partially T
cell depleted allogeneic SCT, in some cases followed by DLI, were
simultaneously analyzed for 10 different MiHA-specific T cells. In
all 6 patients analyzed with the set of combinatorial encoded
MHC multimers, MiHA-specific T cells could be detected. These
Table 2. Characteristics of SCT recipients containing circulating MiHA-specific CD8+ T cells.
UPN Diagnosis
Sex
(Rt/Do) HLA-A HLA-B
DNA MiHA
mismatch
Tetramer+ cells
by dual color
Pre-SCT
Screened material
- Time post SCT
(wks)
Tetramer+ cells
Dual color vs five color*
509 NHL M/F 1 2 8 51 HA-8 ,0.01% 30 post SCT ,0.01% ,0.01%
HY ,0.01% 30 post SCT 0.16% 0.09%
348 CML M/F 1 11 7 8 HY ,0.01% 31 post SCT 0.11% 0.04%
438 NHL F/M 2 31 51 HA-1 No material 62 post SCT 0.02% 0.02%
8605 MM F/M 2 11 51 35 HA-1 ,0.01% 74 post SCT ,0.01% 0.01%
315 AML M/M 3 24 7 35 ACC-1 ,0.01% 68 post SCT 0.04% 0.07%
PANE1 ,0.01% 68 post SCT 1.28% 0.38%
265 AML M/F 2 3 38 47 HA-8 No material 24 post SCT 0.04% 0.04%
HY No material 24 post SCT ,0.01% ,0.01%
*Statistical analysis between dual-color and five-color tetramer analysis was performed using the unpaired t test. The p value is 0.2903.
Abbreviations: Rt, recipient; Do, donor; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma.
doi:10.1371/journal.pone.0021266.t002
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MiHA-specific T cells proliferated upon stimulation with MiHA-
peptide, showing a peptide-dependent response. To confirm
functionality of the MiHA-specific T cells, proliferation upon
stimulation with endogenously processed peptides should be
measured. The specificity of the cells found in the analysis
corresponded to the results obtained by conventional T cell
screenings. The use of a combinatorial MiHA-multimer kit gives a
quick overall view of numerous MiHA-specific T cells within
patient blood samples post SCT. Moreover the amount of patient
material used is equal to what conventional screenings use for just
one specific staining. This method already has been applied as a
tool for the simultaneous detection of autoreactive CD8+ T cells in
blood [11] and now we show that it is a valuable tool for the
concurrent detection of multiple MiHA-specific T cells after
allogeneic SCT and DLI. The MiHA-detection kit used in this
study already covers 10 prevalent MiHA, though flexibility of the
technique allows further expansion of the MiHA set. However, the
current technical limitations regarding the synthesis of HLA-
monomers prevent implementation of certain MiHA, such as
MiHA presented in HLA-B44. The MiHA-detection kit can be
expanded by multimers coupled to additional fluorophores such as
Qdot800 or Qdot565 and Qdot585. It should be noted that these
three fluorophores have a low intensity for which should be
corrected when combining with other fluorophores [7].
Because of the techniques’ potential to screen for large numbers
of different specific T cells [11] and its success in the identification of
melanoma-associated T cell epitopes [7], we tested the potential of
the combinatorial encoding approach to identify new MiHA that
were predicted from a set of polymorphic genes expressed by the
hematopoietic system. For the development of adjuvant tumor-
specific immunotherapy after SCT it is important to enlarge the
spectrum of molecularly identified MiHA that are selectively
expressed in the hematopoietic system and in hematologic
malignancies. Investing in new high throughput methods for MiHA
identification is in our opinion critically important. The recently
developed technique using dual-color-encoded MHC multimers to
detect multiple antigen specific T cells in one sample [7] was tested
for this purpose. The combinatorial encoding approach already led
to the discovery of a new melanoma-associated epitope in a
screening of T cells [7], showing its applicability in these kind of
studies. Our present article describes the prediction of MiHA from
genes with a hematopoietic restricted expression profile and the
verification of these MiHA by screening for MiHA specific CD8+ T
cells in patient PBMC following MHC multimer-based enrichment
and a short-term expansion. A similar reverse immunology
approach of predicting MiHA has already yielded a set of novel
MiHA originating from the Y chromosome presented in HLA-A2
[12]. These male-specific MiHA were verified by means of
ELISPOT showing some of these MiHA to be even more
immunogenic than the well known SMCY.A2 male specific MiHA.
Although this indicates that predicting MiHA can yield actual
functional MiHA, this set of MiHA is not of therapeutic interest
since it is not to be expected that these MiHA have a
hematopoietically restricted expression profile.
Here we performed an analysis using combinatorial encoded
multimers specific for 75 different epitopes. Of the 31 enriched
cultures we screened 17 and found multimer-positive T cells in 5 of
the cultures. One of the specific T cell populations found was
directed against the tumor associated antigen WT-1 for which
specific T cells can be found in CML [13], MDS and AML
patients [14,15]. In the set of predicted candidate MiHA, the gene
WT-1 was integrated because of the presence of SNP rs9332973
resulting in the substitution of a threonin for the alanin at position
6 of the nonameric epitope. Multimers were made for both
epitopes since they had high affinity to HLA-A2, however only the
well known WT-1 epitope yielded an actual T cell response
(0.55%) in patient UPN655 who was diagnosed with AML.
Another epitope to which a high number of CD8+ T cells were
observed was IQLPHLKTL derived from the gene TLR10, which
could not be confirmed by genotyping of the respective recipient-
donor pair. Interestingly, SNP rs11096955 can also lead to the
formation of the LQLPHLKTL epitope, which proved to have
low affinity for HLA-A2 and was discarded for further
experiments. However, the detected TLR10 peptide-specific T
cells could be cross reactive between these two epitopes since the
alternative amino acid is not present at the anchor side to the HLA
molecule. Though several specific responses were detected in the
screening of the enriched patient PBMC, none of these responses
could be validated by conventional tetramer staining or culture
methods. Known HLA-A2-restricted MiHA (i.e. HA-1, HA-2,
HA-8 and SMCY) were added to the screening panel. However,
we only found 1 response for the control MiHA SMCY.A2
(Table 3). DNA of all patients and their corresponding donors used
in the screening was genotyped for the control MiHA. Mismatches
for these MiHA were detected in 6 out of 17 screened patients.
Conventional tetramer staining of the PBMC of these patients
followed by tetramer validation after stimulation with peptide
pulsed EBV-LCL revealed MiHA T cell responses in 4 out of the 6
mismatched patients of which 3 were not found by screening with
the combinatorial encoding set.
A potential benefit of our approach is that the epitopes were
predicted from a set of genes with a restricted expression pattern,
which gives an advantage when looking for tissue restricted
MiHA. However, there are critical limitations of our algorithmic
model and selection criteria for novel candidate MiHA. While
the majority of MiHA identified thus far are derived from allelic
SNPs that generate an amino acid disparity (i.e, nonsynonymous
SNPs) between donor and recipient, other variables may mask
the presence of MiHA or otherwise confound such analyses.
Many MiHA are likely to be encoded by polymorphic cDNAs or
ESTs that are simply not yet represented in GenBank as
translated polypeptides, such as protein isoforms derived from
relatively obscure alternative splicing variants [18], cryptic
translation products [19–21], or perhaps transposable elements
(A.G.B., manuscript in preparation). Another possibility is that
even though a MiHA-encoding gene is represented in GenBank,
its relevant polymorphisms may not yet be fully characterized.
Further complicating the algorithmic prediction of MiHA
peptides is the demonstration that in certain instances, peptides
can be excised and spliced in the proteasome prior to
presentation by MHC [22,23]. Another important caveat is that
the selection of T cells specific for candidate antigens with
Figure 1. Detection of MiHA-specific CD8+ T cells in peripheral blood of patients after SCT and DLI. (A) PBMC collected post SCT stained
with PE- and APC-conjugated tetramers, CD8 AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. The remaining PBMCs were
stimulated once with the MiHA peptide pulsed (10 mM) EBV-LCL of the donor and assayed on day 7 for tetramer+ CD8+ T cells. (B) PBMC stained with
combinatorial encoded MiHA multimers, CD8 AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. Subsequently, cell populations were
analyzed on the Cyan cytometer and re-analyzed by Kaluza 1.1. Cells were gated on CD8+FITC2Sytox Blue2 lymphocytes, and the percentage of
tetramer+ cells among CD8+ T cells is depicted.
doi:10.1371/journal.pone.0021266.g001
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MHC-multimer methodologies or T cell stimulation assays (i.e.,
ELISA, ELISPOT) with exogenously pulsed candidate antigenic
peptides based on cDNA sequence occurs in the absence of
knowledge of post-translational modifications, which can be
critical to determination of immunogenicity [24]. Should reverse
immunology approaches be further employed for the discovery
of MiHA relevant to the immunotherapy of hematologic
malignancies, it will be essential that discovery efforts are
focused on those candidate MiHA polymorphisms with allele
frequencies that ensure frequent donor/recipient disparity.
Although progress has been made over the years to optimize
epitope prediction by reversed immunology, there a still some
hurdles to take before this can be implemented into a, preferably
high throughput method to identify new clinical relevant MiHA.
The concurrent detection of multiple epitope-specific CTL as
described in this manuscript is a step forward in this process but
the identification of novel MiHA by more conventional
approaches should still be taken into consideration. These
approaches make use of CTL clones generated from post-SCT
recipients and recently genome-wide association study (GWAS)
has been used for identification of the epitope recognized by
these CTL ([25], Broen et al. submitted for publication). The
recent addition of several new MiHA identified by GWAS shows
the high feasibility of this approach. Nevertheless also this
approach still is laborious as well as uncertain since clinical
relevance of the discovered MiHA can only be studied in great
detail after the identification has finished.
In conclusion, this study describes the use of combinatorial
encoding MHC-multimers for the concurrent detection of MiHA-
specific T cells after SCT and DLI. Feasibility of this approach was
demonstrated by applying five-color encoded MHC multimers for
a set of 10 known MiHA. In addition, the amount of patient
material required is far less than for conventional, single tetramer
screening. In addition, we determined the potential value of
combinatorial encoding MHC multimers in MiHA identification.
A set of 75 candidate MiHA peptides was predicted from
polymorphic genes with a hematopoietic expression profile.
Monomer-enriched patient PBMC were screened for candidate
MiHA and several epitope-specific T cells were detected during
the screening. Although none of these epitope-specific T cells
could be confirmed by conventional techniques, the concurrent
detection of MiHA specific CD8+ T cells by combinatorial
encoding shows potential as a tool for the detection of multiple T
cell responses.
Materials and Methods
Patient material
All patients in this study were admitted in our transplantation
program from May 1996 onwards. Patients underwent HLA
identical allogeneic SCT using a T cell-depleted stem cell graft
containing a fixed number of 0.56106 T cells/kg body weight.
Several patients also underwent subsequent prophylactic or
therapeutic DLI. Peripheral blood samples of patients were
collected after written informed consent in ongoing clinical stem
cell transplantation protocols approved by the Radboud Univer-
sity Nijmegen Medical Centre (RUNMC) Institutional Review
Board.
Cell isolation and culture
CD8+ T cell bulk cultures were generated from peripheral blood
mononuclear cells (PBMC) obtained after SCT and cultured in
Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen,
Carlsbad, CA) supplemented with 10% human serum (HS;
Sanquin blood bank, Nijmegen, the Netherlands). After initial
stimulation, 100 IU/ml IL-2 (Chiron, Emeryville, CA) and 10 ng/
ml IL-15 (BD) were added at day 2. Flow cytometric analysis was
performed at day 7. All Epstein-Barr virus lymphoblastoid cell
lines (EBV-LCL) were cultured in IMDM/10% fetal calf serum
(FCS; Integro, Zaandam, The Netherlands).
Figure 2. Detection of peptide-specific T cells by the combinatorial encoding MiHA-multimer assay. (A) Ten different flow cytometric
dot plots showing thawed PBMC of representative patient UPN348, stained with the combinatorial encoded MiHA-multimer assay using the peptide
set as described in Table 1. The combination of multimers coupled to PE and to Qdot605 shows a positive response, corresponding to multimer-
SMCY.A2+ T cells. Cells were stained with MiHA multimers, CD8 AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. Subsequently, cell
populations were analyzed by flow cytometry. Cells were gated on CD8+FITC2Sytox Blue2 lymphocytes and corrected for single, triple or quadruple
multimer-positive cells. The percentage of multimer+CD8+ T cells is depicted. (B) Ten different dot plots showing PBMC of representative patient
UPN348 after culturing with SMCY.A2-peptide pulsed donor EBV-LCL. Only the response observed in non-cultured PBMC show an increase of
multimer-SMCY.A2+ T cells. Staining and analysis was performed as described under (A).
doi:10.1371/journal.pone.0021266.g002
Figure 3. ELISA-based HLA-A2 affinity assay for 107 in silico
predicted potential MiHA. HLA-A2 monomers containing UV
degradable peptide were exchanged with 107 predicted MiHA peptides
and HLA-A2 binding affinity was tested. Results show 32 low binders
(OD#0.39), 33 intermediate binders (OD 0.4–0.124) and 42 high binders
(OD$1.25). Data are depicted as mean of triplicate wells.
doi:10.1371/journal.pone.0021266.g003
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SNP genotyping assays
Genotyping of HLA-matched SCT donor-recipient pairs for
known MiHA was conducted using the KASPar assay, a
fluorescence-based competitive allele-specific PCR that utilizes
non-labeled primers (KBioscience, Herts, UK). Details of the
process and primer sequence can be obtained from KBioscience.
SNP genotyping for verification of immunogenic epitopes was
performed by Taqman SNP genotyping according to manufac-
turer’s recommendation (Applied Biosystems [ABI], Foster City,
CA). Briefly, 10 ng of gDNA was amplified using ABI pre-
designed SNP genotyping assays. 5 ul of gDNA (2 ng/ml) was
combined with 12.5 ml of TaqMan Universal PCR Master Mix
(26) and 1.25 ml appropriate genotyping assay reagent containing
specific forward and reverse primers and specific FAM/VIC
probes (206) in a total reaction volume of 25 ml. Reactions were
run on the ABI 9700 thermal cycler in a 96 well format for 1 cycle
at 95uC610 minutes followed by 40 cycles at 92uC615 seconds,
60uC61 minute. A post-PCR plate read for FAM/VIC was
performed on the ABI 9700HT and genotype calls were generated
using SDS 2.3 software (ABI).
Figure 4. PBMC of a healthy donor enriched for virus-specific T cells. Peripheral blood of an HLA-A2+ healthy donor was enriched for EBV-
and CMV-specific CD8+ T cells. Before culture there were low amounts of EBV- and CMV-specific CD8+ T cells present, which showed an increase after
enrichment and 16 days of culture. Cells were stained with tetramers coupled to PE and gated on CD8+tetramer+. Analysis was performed on the
Cyan cytometer.
doi:10.1371/journal.pone.0021266.g004
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Prediction of HLA-A2-restricted candidate MiHA
To predict HLA-A2-restricted MiHA within hematopoiesis
restricted gene products, adaptable software was written in the
Java language. This software utilizes the Entrez retrieval system
(http://www.ncbi.nlm.nih.gov/entrez) within the NCBI’s Gen-
Bank sequence repository to extract from a database of all known
human amino acid sequences (ftp://ftp.ncbi.nlm.nih.gov/
genomes/H_sapiens/protein) the accession numbers of amino
acid variations derived from allelic non-synonymous SNPs, as
represented in GenBank’s dbSNP database. The software
algorithm then parses the retrieved files of polymorphisms and
implements the predictive HLA-binding algorithm described by
Parker et al. [26] on peptides from these files that encompass the
polymorphism within a nine- or ten-mer offset window, using
HLA-A2-specific coefficient files from the BIMAS website (http://
www-bimas.cit.nih.gov/molbio/hla_bind/). Algorithmic input of
gene expression data for hematopoiesis biased genes included, but
were not limited to, the following resources: downloadable gene
expression data sets from the Whitehead Institute for Genomics
Research pertaining to expression differences between ALL and
AML [27], genes upregulated in ALLs carrying a chromosomal
translocation involving the mixed-lineage leukemia gene (MLL)
(http://www-genome.wi.mit.edu/cgi-bin/cancer/datasets.cgi); dif-
fuse large B-cell lymphoma gene expression profiling data sets from
the Lymphoma/Leukemia Molecular Profiling Project website
(http://llmpp.nih.gov/); a hematopoietic stem cell database at the
StemCell Database website (http://stemcell.mssm.edu/v2/); and the
human HapMap project at http://www.hapmap.org. In addition,
manually retrieved accession numbers of hematopoietically biased
genes described in the current literature represented amajor source of
input data for the algorithm.
Generation of peptide-MHC multimers
Peptide-MHCmultimers were produced by UV-mediated ligand
exchange as previously described by Rodenko et al. [9]. The ligand
used for the construction of MHC class I was a UV-sensitive peptide
containing a (2-nitro)phenylglycine residue which is cleaved upon
UV irradiation, making the MHC molecule peptide-receptive and
capable of being loaded with epitopes of choice. The expression,
purification and refolding of MHC heavy and light chains were
performed as described by Gorboczi et al. [28].
Peptide-HLA-A2-based affinity ELISA
Affinity of the predicted MiHA epitopes to HLA-A2 was tested
by an HLA-A2 affinity streptavidin-based sandwich ELISA
described by Rodenko et al. [9]. Briefly, 96-well plates were
coated with streptavidin to which biotinylated monomers,
containing all different predicted peptides, were added. Next, an
HRP-conjugated anti-b2m antibody was added, binding to all
stable MHC class I molecules. 2,29-azino-bis(3-ethylbenzthiazo-
line-6-sulphonic acid) was added and the green-colored oxidation
product was measured at OD 414 nm.
Enrichment of peptide-specific T cells
PBMCs were obtained from CMV+ and EBV+ buffy coats
(Sanquin blood bank, Nijmegen, the Netherlands) or from patients
after SCT or DLI. All enrichments were performed on
cryopreserved material. PBMC were stained with PE-labeled
MHC multimers (1 ml of each individual PE-multimer for 107
PBMC) for 1 hour at 4uC. In case of the CMV/EBV enrichment a
total of 2 ml PE-multimer for each specific epitope was added,
while in case of enrichment for the candidate MiHA panel a 79 ml
PE-multimer mix consisting of 1 ml of each candidate and control
MiHA epitope was added. Subsequently, cells were washed twice,
and incubated with 20 ml magnetic beads coated with anti-PE
antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). Mag-
netically labeled cells were isolated by MACS (Miltenyi Biotech)
using a MS Column following the manufacturer’s protocol. Eluted
cells were washed and resuspended in IMDM supplemented with
10% human serum, 100 IU/ml IL-2 and 10 ng/ml IL-15 (BD).
On day 1, 26104 irradiated (60 Gy) autologous feeder cells were
added along with 2,500 CD2/CD3/CD28 loaded anti-Biotin
MACSiBead Particles (Miltenyi Biotec). On day 8, to prevent
overgrowth by CD4+ T cells, T-cell cultures were depleted of
residual CD4+ T cells via the addition of 50 ml of BD IMag anti-
human CD4 particles (BD Biosciences) per 107 total cells and
treatment per manufacturers’ protocol. Cultures were split and
refreshed biweekly with medium plus cytokines. After 2–3 weeks,
cell cultures were counted and tested for the presence of peptide-
specific CD8+ T cells using combinatorial MHC multimer
staining.
Combinatorial MHC multimer staining
Combinatorial MHC multimer stainings were performed on
either thawed PBMC samples or ex vivo expanded T cell cultures.
For this, 16106 PBMCs or 1–56105 cultured T cells were
incubated with 1 ml of every single MHC multimer (final
concentration 2 mg/ml per MHC based on initial monomer
concentration) in a total volume of 80 ml for 15 min at room
temperature in the dark. Subsequently, an antibody mixture
consisting of 0.8 ml CD8-Alexa700 (Invitrogen, Carlsbad, CA),
4 ml CD4-FITC (Beckman Coulter), 2 ml CD14-FITC (BD), 2 ml
CD19-FITC (Dako), 6 ml CD16-FITC (BD) was added, and cells
were incubated for 30 min at 4uC. Finally, cells were washed twice
and Sytox Blue (Invitrogen) was added at a final dilution of 1:5000
to allow dead cell exclusion. Data acquisition was performed on a
Cyan-ADP analyzer (Beckman Coulter) and analyzed by Kaluza
1.1 software (Beckman Coulter). Antigen-specific T cells were
quantified using an identical gating strategy as described by
Hadrup et al. [7] and Velthuis et al [11]. First, viable Sytox Blue-
negative, single-cell lymphocytes were gated. Subsequently, CD8-
positive and FITC (CD4, CD14, CD16, CD19) negative cells
were selected. MHC multimer positive cells were gated as CD8+
T cells positive in two MHC multimer channels (APC, PE,
Qdot605, Qdot655, Qdot705 and Qdot800) and negative in
the four other MHC multimer channels. In order to validate
Table 3. Percentage of dual-color tetramer+CD8+ T cells in
PBMC samples of transplanted patients screened after MHC-
multimer based enrichment and short-term expansion.
Gene
Candidate
MiHA UPN466 UPN541 UPN665 UPN407 UPN427
WT-1 RMFPNAPYL 0.55a
BPI KLQPYFQTL 0.28 0.09 0.07 0.04
LAG3 LTLGVLSLL 0.19b
IGLL1 LMNDFYLGI 0.10
GPR109b FLLEFLLPL 0.23 0.04
CCRL2 ILATLPEFV 0.07
CARD8 YLVPSDALL 0.01b
TLR10 IQLPHLKTL 0.47
SMCY.A2 FIDSYICQV 0.07b
aKnown WT-1 epitope.
bT cell response confirmed by SNP genotyping.
doi:10.1371/journal.pone.0021266.t003
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dual-color coded CD8+ T cells, PBMC were cultured in IMDM
10% HS and stimulated with irradiated EBV-LCL expressing the
appropriate HLA restriction molecule. After initial stimulation,
100 IU/ml IL-2 (Chiron) and 10 ng/ml IL-15 (BD) was added at
day 2. Primary T cell cultures were analyzed by flow cytometry at
day 7.
Supporting Information
Table S1 Screening pool of high and intermediate binding
HLA-A2 peptides set up with combinations of labeled MHC
multimers.
(DOCX)
Figure 5. Detection of multiple peptide-specific CD8+ T cells after enrichment of patient PBMC. Fifteen different dot plots showing
multimer-enriched PBMC of representative patient UPN665 stained with the combinatorial encoded MiHA assay using the multimers of pool A.
Epitope-specific T cells were detected for RMFPNAPYL (APC and Qdot705) and KLQPYFQTL (Qdot605 and Qdot655). In addition to double positive
cells, single positive cells for either APC, Qdot605, Qdot655 or Qdot705 are visible in their respective channels. Cells were stained with multimers, CD8
AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. Subsequently, cell populations were analyzed by flow cytometry. Cells were gated
on CD8+FITC2Sytox Blue2 lymphocytes and corrected for single, triple, quadruple or quintuple multimer positive cells. The percentage of
tetramer+CD8+ T cells is depicted in the dot plots.
doi:10.1371/journal.pone.0021266.g005
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